News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,454 Results
Type
Article (14051)
Company Profile (304)
Press Release (249099)
Section
Business (79550)
Career Advice (152)
Deals (13236)
Drug Delivery (34)
Drug Development (50471)
Employer Resources (31)
FDA (5702)
Job Trends (5132)
News (144478)
Policy (10037)
Tag
Academia (903)
Alliances (21613)
Alzheimer's disease (779)
Antibody-drug conjugate (ADC) (67)
Approvals (5689)
Artificial intelligence (82)
Bankruptcy (99)
Best Places to Work (4554)
Biotechnology (249)
Breast cancer (121)
Cancer (1012)
Cardiovascular disease (83)
Career advice (132)
CAR-T (82)
Cell therapy (246)
Clinical research (40424)
Collaboration (381)
Compensation (152)
COVID-19 (1018)
C-suite (99)
Cystic fibrosis (72)
Data (1051)
Diabetes (97)
Diagnostics (1218)
Earnings (29146)
Events (47494)
Executive appointments (309)
FDA (6129)
Funding (362)
Gene editing (70)
Gene therapy (180)
GLP-1 (329)
Government (1067)
Healthcare (6581)
Infectious disease (1059)
Inflammatory bowel disease (100)
IPO (7241)
Job creations (859)
Job search strategy (127)
Layoffs (191)
Legal (1379)
Lung cancer (147)
Lymphoma (63)
Manufacturing (93)
Medical device (2564)
Medtech (2565)
Mergers & acquisitions (6176)
Metabolic disorders (289)
Neuroscience (1062)
NextGen: Class of 2025 (2014)
Non-profit (851)
Northern California (1212)
Obesity (156)
Opinion (93)
Parkinson's disease (82)
Patents (69)
People (25246)
Phase I (14276)
Phase II (18795)
Phase III (11892)
Pipeline (449)
Postmarket research (851)
Preclinical (5994)
Radiopharmaceuticals (208)
Rare diseases (223)
Real estate (1414)
Regulatory (8370)
Research institute (934)
Series A (71)
Southern California (1083)
Startups (1968)
United States (9574)
Vaccines (175)
Weight loss (92)
Date
Today (74)
Last 7 days (238)
Last 30 days (1170)
Last 365 days (20450)
2025 (1107)
2024 (20620)
2023 (22448)
2022 (26871)
2021 (27873)
2020 (23427)
2019 (16271)
2018 (11762)
2017 (13793)
2016 (11887)
2015 (14372)
2014 (10412)
2013 (7490)
2012 (7538)
2011 (7616)
2010 (7429)
Location
Africa (146)
Asia (17044)
Australia (2874)
California (2754)
Canada (873)
China (250)
Colorado (103)
Connecticut (116)
Europe (36713)
Florida (308)
Georgia (79)
Illinois (170)
Indiana (67)
Maryland (366)
Massachusetts (2181)
Minnesota (111)
New Jersey (683)
New York (753)
North Carolina (445)
Northern California (1212)
Ohio (88)
Pennsylvania (525)
South America (207)
Southern California (1083)
Texas (312)
Washington State (273)
263,454 Results for "tcr2 therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
March 11, 2024
·
5 min read
Drug Development
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting
Alaunos Therapeutics, Inc. announced that the Company will present early translational data from the first three patients treated in its ongoing TCR-T Library Phase 1/2 trial at the 2023 American Society of Clinical Oncology Annual Meeting taking place June 2-6, 2023, at the McCormick Place Convention Center in Chicago.
May 25, 2023
·
7 min read
Drug Development
TCR2 Therapeutics’ Gavo-Cel Shows Early Promise in Solid Tumors, Ovarian Cancer
TCR2 Therapeutics announced promising Phase I data for gavo-cel in mesothelin-expression that points toward effects in multiple solid tumors, especially ovarian cancer.
September 28, 2022
·
3 min read
·
Mark Terry
Genetown
TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2022
Therapeutics Inc. announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 7,600 shares of TCR2’s common stock to 2 new non-executive employees.
September 1, 2022
·
2 min read
Pharm Country
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
Adaptimmune Therapeutics plc (NASDAQ: ADAP) today announced completion of an all-stock transaction in which Adaptimmune has combined with TCR² Therapeutics Inc.
June 1, 2023
·
10 min read
Drug Development
Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
Alaunos Therapeutics, Inc. today announced early clinical data from the first patient in its ongoing TCR-T Library Phase 1/2 trial.
September 21, 2022
·
6 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Drug Development
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
TCR 2 Therapeutics Inc. today announced that the Company plans to discuss the complete Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors in a premarket press release and conference call to be held on Wednesday, September 28th, 2022 at 8:00am E.T.
September 27, 2022
·
1 min read
Genetown
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 08, 2023
TCR2 Therapeutics Inc. announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 2,000 shares of TCR2’s common stock to one non-executive new hire.
May 8, 2023
·
2 min read
Genetown
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 03, 2023
TCR2 Therapeutics Inc. announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 6,000 shares of TCR2’s common stock to two non-executive new hires.
April 3, 2023
·
2 min read
1 of 26,346
Next
